Sarepta Therapeutics (SRPT) closed at $18.56 on October 21, 2026, down 3.2% from the previous close, on volume of 1,912,767 shares (30-day average 2,923,749).
Data as of October 21, 2026.
21-Oct-2026
Sarepta Therapeutics (SRPT) Receives a Rating Update from a Top Analyst
TipRanks (Wed, 21-Oct 8:57 AM ET)
TipRanks (Mon, 19-Oct 8:00 AM ET)
TipRanks (Mon, 19-Oct 6:30 AM ET)
Business Wire (Wed, 14-Oct 8:30 AM ET)
Business Wire (Mon, 5-Oct 1:26 PM ET)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 30-Sep 4:30 PM ET)
Business Wire (Wed, 30-Sep 8:30 AM ET)
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
Business Wire (Fri, 25-Sep 8:30 AM ET)
Business Wire (Thu, 24-Sep 8:30 AM ET)
Business Wire (Tue, 8-Sep 9:00 AM ET)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Sarepta Therapeutics trades on the NASDAQ stock market under the symbol SRPT.
As of October 21, 2026, SRPT stock price declined to $18.56 with 1,912,767 million shares trading.
SRPT has a beta of 2.25, meaning it tends to be more sensitive to market movements. SRPT has a correlation of 0.17 to the broad based SPY ETF.
SRPT has a market cap of $1.96 billion. This is considered a Small Cap stock.
Last quarter Sarepta Therapeutics reported $401 million in Revenue and $.64 earnings per share. This beat revenue expectation by $37 million and exceeded earnings estimates by $.18.
In the last 3 years, SRPT traded as high as $173.25 and as low as $10.42.
The top ETF exchange traded funds that SRPT belongs to (by Net Assets): IJR, XBI, VTI, IWM, VB.
SRPT has underperformed the market in the last year with a return of -19.5%, while SPY returned +16.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SRPT shares. However, SRPT has outperformed the market in the last 3 month and 2 week periods, returning +10.3% and +7.2%, while SPY returned +4.4% and -0.8%, respectively. This indicates SRPT has been having a stronger performance recently.
SRPT support price is $18.43 and resistance is $19.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRPT shares will trade within this expected range on the day.
